Trial Profile
A prospective randomized, open-label, 16 weeks study to compare the effect of vildagliptin and gliclazide on inflammatory markers, in type 2 diabetes mellitus inadequately controlled with metformin
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jul 2015
Price :
$35
*
At a glance
- Drugs Gliclazide (Primary) ; Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 28 Jul 2015 New trial record
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.